Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.49 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach to future growth. They highlighted the need for continued focus on cost management.
Management did not provide specific guidance for future quarters.
The company is focusing on improving operational efficiencies.
Natera's earnings report shows a loss per share of $0.49, indicating challenges in profitability. The stock reacted negatively, declining by 3.19%, likely due to the lack of revenue information and forward guidance. Investors may be concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018